Date published: 2025-10-22

1-800-457-3801

SCBT Portrait Logo
Seach Input

PLK4 Inhibitors

PLK4 inhibitors represent a specific class of small molecules that target Polo-like kinase 4 (PLK4), a serine/threonine-protein kinase that plays a critical role in the regulation of centriole duplication during the cell cycle. PLK4 is a unique member of the Polo-like kinase family, characterized by its distinct structure and function compared to other family members such as PLK1, PLK2, and PLK3. This kinase is essential for the initiation of centriole biogenesis, a process crucial for the formation of centrosomes, which serve as the main microtubule-organizing centers in animal cells. Aberrant PLK4 activity can lead to centrosome amplification, resulting in chromosomal instability and aneuploidy, which are hallmark features of various abnormal cellular processes. The design of PLK4 inhibitors, therefore, focuses on specifically disrupting the kinase's ability to regulate centriole duplication, providing a precise tool for modulating centrosome numbers within a cell. The chemical structure of PLK4 inhibitors typically includes features that enable these molecules to selectively bind to the ATP-binding pocket of PLK4, thereby preventing its phosphorylation activity. Many PLK4 inhibitors exhibit high selectivity for PLK4 over other kinases, which is critical given the complex network of kinase signaling pathways within cells. Structural biology and computational chemistry have played significant roles in the design and optimization of these inhibitors, providing insights into the conformational dynamics of PLK4 and its interaction with various ligands. The development of PLK4 inhibitors has involved a combination of high-throughput screening, structure-based drug design, and medicinal chemistry to refine their potency, selectivity, and pharmacokinetic properties. By modulating PLK4 activity, these inhibitors are invaluable tools for studying the molecular mechanisms of centriole duplication and centrosome biology, shedding light on fundamental aspects of cell cycle regulation and its implications in cellular homeostasis.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

XMD 8-92 (free base)

1234480-50-2sc-364068
sc-364068A
sc-364068B
sc-364068C
5 mg
10 mg
100 mg
1 g
$235.00
$340.00
$1700.00
$10330.00
10
(0)

XMD 8-92 (free base) acts as a potent inhibitor of PLK4, showcasing unique molecular interactions that disrupt the kinase's activity. Its structural features facilitate specific binding to the ATP-binding site, altering the conformational dynamics of the enzyme. This interaction leads to a distinct modulation of phosphorylation pathways, impacting cellular processes such as centriole biogenesis. Additionally, its stability in various solvents enhances its reactivity, allowing for intricate studies of kinase regulation.

Taxol

33069-62-4sc-201439D
sc-201439
sc-201439A
sc-201439E
sc-201439B
sc-201439C
1 mg
5 mg
25 mg
100 mg
250 mg
1 g
$40.00
$73.00
$217.00
$242.00
$724.00
$1196.00
39
(2)

Stabilizes microtubules, disrupting mitosis and potentially influencing PLK4 activity.

Nocodazole

31430-18-9sc-3518B
sc-3518
sc-3518C
sc-3518A
5 mg
10 mg
25 mg
50 mg
$58.00
$83.00
$140.00
$242.00
38
(2)

Disrupts microtubule dynamics, potentially impacting PLK4 activity during mitosis.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$173.00
$418.00
43
(3)

DNA intercalating agent, can cause DNA damage and affect cell cycle progression, indirectly impacting PLK4.

Etoposide (VP-16)

33419-42-0sc-3512B
sc-3512
sc-3512A
10 mg
100 mg
500 mg
$32.00
$170.00
$385.00
63
(1)

Inhibits topoisomerase II, affecting DNA replication and potentially influencing PLK4.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$57.00
$182.00
$92.00
21
(2)

Inhibits topoisomerase I, can affect DNA replication, potentially impacting PLK4.

Fluorouracil

51-21-8sc-29060
sc-29060A
1 g
5 g
$36.00
$149.00
11
(1)

Inhibits thymidylate synthase, disrupting DNA synthesis and potentially influencing PLK4.

Hydroxyurea

127-07-1sc-29061
sc-29061A
5 g
25 g
$76.00
$255.00
18
(1)

Inhibits ribonucleotide reductase, affecting DNA replication and potentially PLK4 activity.

2′-Deoxy-2′,2′-difluorocytidine

95058-81-4sc-275523
sc-275523A
1 g
5 g
$56.00
$128.00
(1)

Nucleoside analog, can disrupt DNA synthesis and potentially affect PLK4.

Bleomycin Sulfate

9041-93-4sc-200134
sc-200134A
sc-200134B
sc-200134C
10 mg
50 mg
100 mg
500 mg
$206.00
$612.00
$1020.00
$2856.00
38
(3)

Induces DNA breaks, potentially impacting PLK4 activity in the cell cycle.